

Executive Summary LC 2



Xylazine and Access to Health Care

- Access to health care: a social determinant of health that is critical for reducing health inequities in our communities
- **Xylazine** is a veterinary sedative being introduced to Cincinnati's illicit drug supply. Ingestion of this drug can lead to dangerous necrotic wounds and risk for overdose.
- Access to drug-checking equipment is emerging as an essential public health service. This includes utilizing test strips to identify a contaminated drug supply.

Community Impact of Xylazine

- On a national scale, overdoses involving xylazine increased 273% between 2019-2022.
- In a survey of Ohio drug users, 73% indicated they did not want to use xylazine and 53% were unaware that xylazine was present in "street drugs."
- Xylazine test strips have demonstrated high sensitivity (100%), specificity (85%), and precision (91%).

Policy Status in Cincinnati

- Ohio Section 2925.14 covers law regarding drug paraphernalia.
 - Knowingly using paraphernalia or possessing paraphernalia with a purpose to use it is a misdemeanor of the fourth degree.
 - As of April 2023, excludes drug testing strips to determine presence of fentanyl or fentanyl-related compound as paraphernalia.
 - There are no exclusions currently for xylazine test strips.

Rationale for Policy Modification

- A survey of people who inject drugs in Rhode Island found that a positive fentanyl test strip resulted in safer usage behaviors.
- Expanding the use of xylazine test strips in our communities could help decrease its harmful effects on those who are ingesting it unknowingly, as was seen with fentanyl.

Proposed Advocacy Strategy

- Using data-driven advocacy and personal testimonials, we hope to engage legislators and draft an updated exemption to Section 2925.14.
- We ask for support and co-sponsorship to amend Section 2925.14 D4 to exclude xylazine test strips.